Novacyt Group – at the forefront of clinical diagnostics innovation
Novacyt is an international specialist diagnostics group, developing and manufacturing diagnostic and pathogen testing kits based on molecular and protein testing technologies for the human clinical, life science, food, and industrial markets.
We believe in providing high-quality innovations, with a patient-led focus, which advance the science behind diagnostics in microbiology, haematology, and serology testing.
The Novacyt Group has grown progressively in recent years, adding new business solutions to meet a growing range of customer needs. The Group includes:
Primerdesign: focused on the design, manufacture, validation and supply of gold standard real-time PCR kits, reagents, and instruments. We provide the best customer qPCR assay development service in the world, offering bespoke and commercialisation of real-time PCR supported by an agile team that delivers to market in the shortest possible time.
Microgen Bioproducts: dedicated to diagnostic solutions in microbiology, serology, haematology, bacteriology, and virology. We support healthcare providers in improving patient health, plus a comprehensive food diagnostic range that helps manufacturers ensure consumer safety.
IT-IS International: specialising in the development and manufacture of molecular diagnostic instrumentation. With comprehensive capabilities ranging from molecular biology to software engineering, we provide products from bespoke system developments to off-the-shelf real-time PCR machines.
Lab 21 Healthcare: providing cost-effective solutions in the production and distribution of reagents and test kits for both IVD and blood grouping application - known for manufacturing and supplying Plasmatec and Biotec branded products.
At Novacyt, we pride ourselves on our long-established track record in diagnostic solutions, with a wealth of in-house research and development expertise.
This pedigree in product development stood us in good stead as the COVID-19 pandemic broke. With a heritage of clinical diagnostic testing in the food and veterinary industries, we had developed into a leading infectious diseases clinical diagnostics company, covering respiratory and transplant therapy areas. Before the pandemic, the company built an ethos of agility and speed in responding to virus outbreaks such as bird flu, Ebola, and Zika Virus with breakthrough diagnostics tests. This R&D expertise, flexibility and pace pre-determined our ability to respond to the Sars-CoV-2 outbreak.
We developed one of the first tests in the world for COVID-19, achieving the CE mark and regulatory approval in February 2020. Throughout 2020, we continued to create, validate, and launch new products for COVID-19. Our market-leading bio surveillance capabilities ensure an emphasis on tracking and responding to emerging new variants and near-to-patient testing requirements.
In addition, our growing ability to run clinical trials, and our in-house regulatory expertise, provide a fully integrated approach from discovery, development, and clinical trial design to regulatory submission.